Perioperative management of a patient with glanzmann's thrombasthenia for mitral valve repair under cardiopulmonary bypass

Abstract

A 30-year-old male patient presented with Glanzmann's thrombasthenia and mitral valve prolapse. He was in acute decompensated congestive heart failure due to severe mitral and tricuspid regurgitation. After his cardiac failure had been stabilized, the patient was subjected to mitral and tricuspid valve repair. His transfusion requirements were guided by thrombelastography and his bleeding disorder was managed by infusing single donor plasmapheresed platelet transfusions in the perioperative period. The patient underwent surgery uneventfully.

Point-of-Care Testing in Patients with Hereditary Disorders of Primary Hemostasis: A Narrative Review

“…Relatively many studies described the use of TEG and ROTEM in patients with PFDs. However, the vast majority of these studies consists of case reports involving patients undergoing surgical procedures 136 137 138 139 140 141 142 143 144 145 or during peripartum care. 146 147 148 149 150 151 152…”

“…132 Relatively many studies described the use of TEG and ROTEM in patients with PFDs. However, the vast majority of these studies consists of case reports involving patients undergoing surgical procedures [136][137][138][139][140][141][142][143][144][145] or during peripartum care. [146][147][148][149][150][151][152] In GT, viscoelastic assays unequivocally have shown decreased clot strength (MA/maximal clot firmness).…”

Anti‐platelet treatment challenges in Glanzmann thrombasthenia‐clinical practice when data lacks

“…Although there are many case reports with different management strategies in the settings of non-cardio-vascular surgery, to date there are few reports about the treatment of such subjects in cardiac surgery [7][8][9] and only one describes the clinical scenario of a patient with GT requiring coronary stent implantation and dual antiplatelet treatment 10 ; the latter despite significant cardiac ischemia could not be stented due to severe haemorrhage in the first two days of dual antiplatelet challenge.…”